

ACME Laboratories Ltd. (DSE : ACMELAB)	
Current Price (November 10, 2016)	100.2
Total Number of Share (mn)	211.6
Free Float (%)	60.4%
Annualized PE– ACMELAB*	19.3x
Trailing PE – ACMELAB *	19.3x
Annualized PE – Pharmaceuticals	21.6X

* Based on annualized earnings of the latest declaration

Financials (BDT mn)**	2014	2015	2016
Revenue	10,218	11,496	12,645
Gross profit	3,980	4,301	4,874
Operating profit	1,934	2,358	2,542
Net profit after tax	894	922	1,101
Total assets	22,180	23,260	28,890
Total equity	10,692	11,373	16,364

Growth (%)	2014	2015	2016
Revenue	13.9%	12.5%	10.0%
Net profit after tax	76.8%	3.1%	19.5%

Per share (BDT)	2014	2015	2016
Diluted EPS	4.2	4.4	5.2
Diluted BVPS	50.5	53.7	77.3

Others	2014	2015	2016
Gross profit margin	39.0%	37.4%	38.5%
Operating profit margin	18.9%	20.5%	20.1%
Net profit after tax margin	8.7%	8.0%	8.7%
ROA	4.6%	4.1%	4.2%
ROE	8.8%	8.4%	7.9%
Stock Dividend	-	-	-
Cash Dividend	-	-	35.0%

** Accounting year Jun-Jul

Terminologies

Free Float : % of total shares not owned by Sponsors/ Directors, and Govt.
Annualized PE: Based on Annualized Earnings of the latest declared quarter
Trailing PE: Based on Latest 12 Months Earnings

Company Profile

The ACME Laboratories Limited (DSE: ACMELAB) is a leading pharmaceutical company that was established in 1954. By 2014 the company enlarged its product portfolio to over 500 products for human and over 160 veterinary products. ACMELAB has a strong footing in local pharmaceutical market as well as a global exposure through its export business. The company was listed both in DSE and CSE in 2016 under the book building method.


Key Revenue Drivers & Company Insight

The Company is engaged in manufacturing marketing and distribution of generic pharmaceuticals formulation products for human and veterinary medical needs. The company's top line stood at BDT 12,645 mn adjusted for VAT on 2016. 99% of the company's gross revenue comes from selling of own manufactured goods.

The company has been maintaining a history of double digit growth in recent past, leveraging on the growing demand of pharmaceutical products backed by rising living standard and per capita medical expenses. During 2016, revenue grew by 10.0% YoY, which is lower compared to 12.5% and 13.9% YoY growth in 2015 and 2014, respectively. In 2016, ACMELAB's business grew by 11.4% YoY in the domestic market, but overall growth was lower than that because of 15.2% YoY plunge in export business

Financial Performance

On the back of 10.0% top line growth in 2016, Net profit after tax surged by 19.5% as profit margins improved for the company. Gross profit margin stood at 38.5% in 2016, compared to 37.4% in 2015. However, Operating profit margin declined marginally to 20.1% in 2016, as against 20.5% in 2015. Ultimately, profit boosted at Net profit after tax margin rose to 8.7% in 2016, compared to 8.0% a year before, helping the company secure the robust bottom line growth.



Source : DSE; IDLCIL